Brief: Inozyme Pharma Announces Positive Preliminary Data From Phase 1/2 Clinical Trial Of INZ-701 In Patients With ENPP1 Deficiency

Inozyme Pharma

04/04/2022 12:33

April 4 (Reuters) - Inozyme Pharma Inc  INZY.O :
    * INOZYME PHARMA ANNOUNCES POSITIVE PRELIMINARY DATA FROM
PHASE
1/2 CLINICAL TRIAL OF INZ-701 IN PATIENTS WITH ENPP1 DEFICIENCY
    * INOZYME PHARMA INC - RAPID, SIGNIFICANT, SUSTAINED
INCREASE IN
PLASMA PYROPHOSPHATE (PPI) LEVELS OBSERVED IN ALL THREE PATIENTS
IN LOWEST DOSE COHORT
    * INOZYME PHARMA INC - PPI INCREASED IN ALL THREE PATIENTS
TO
LEVELS COMPARABLE TO THOSE OBSERVED IN A STUDY OF HEALTHY
SUBJECTS
    * INOZYME PHARMA INC - INZ-701 WAS GENERALLY WELL-TOLERATED
AND
EXHIBITED A FAVORABLE INITIAL SAFETY PROFILE
    * INOZYME PHARMA INC - SECOND COHORT UNDERWAY AT NEXT DOSE
LEVEL
(0.6 MG/KG)
    * INOZYME PHARMA INC - HALF-LIFE OF INZ-701 OBSERVED IN
TRIAL
SUGGESTS POTENTIAL FOR ONCE-WEEKLY DOSING
    * INOZYME PHARMA INC - INOZYME PLANS TO REPORT TOPLINE DATA
FROM
ONGOING TRIAL IN SECOND HALF OF 2022

Source text for Eikon:  ID:nGNX1bVwmL 
Further company coverage:  INZY.O 

 ((Reuters.Briefs@thomsonreuters.com;))